Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;69(8):1374-1376.
doi: 10.1136/gutjnl-2020-320692. Epub 2020 Mar 13.

Changing TACTICS in intermediate HCC: TACE plus sorafenib

Pompilia Radu  1 , Jean-François Dufour  2   3
Affiliations
Comment

Changing TACTICS in intermediate HCC: TACE plus sorafenib

Pompilia Radu et al. Gut. 2020 Aug.
No abstract available

Keywords: cancer; liver.

PubMed Disclaimer

Conflict of interest statement

Competing interests: J-FD: advisory committees: Bayer, BMS, Falk, Genfit, Genkyotex, Gilead Science, HepaRegenix, Intercept, Eli Lilly, Merck, Novartis; Speaking and teaching: Bayer, Bristol-Myers Squibb, Intercept, Genfit, Gilead Science and Novartis.

Comment on

References

    1. Marrero JA, Kulik LM, Sirlin CB, et al. . Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 2018;68:723–50. 10.1002/hep.29913 - DOI - PubMed
    1. Omata M, Cheng A-L, Kokudo N, et al. . Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317–70. 10.1007/s12072-017-9799-9 - DOI - PMC - PubMed
    1. Korean Liver Cancer Association, National Cancer Center . 2018 Korean liver cancer Association-National cancer center Korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver 2019;13:227–99. 10.5009/gnl19024 - DOI - PMC - PubMed
    1. Bolondi L, Burroughs A, Dufour J-F, et al. . Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012;32:348–59. 10.1055/s-0032-1329906 - DOI - PubMed
    1. Lencioni R. Loco-Regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762–73. 10.1002/hep.23725 - DOI - PubMed